A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Summary

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Psychosis Associated With Alzheimer's Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

55 to 90 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Last updated on ClinicalTrials.gov

September 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites